EntryPoint Capital LLC Acquires Shares of 49,093 MiMedx Group, Inc. (NASDAQ:MDXG)

EntryPoint Capital LLC bought a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 49,093 shares of the company's stock, valued at approximately $472,000.

Several other large investors have also recently bought and sold shares of MDXG. JPMorgan Chase & Co. boosted its position in MiMedx Group by 265.4% during the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock worth $1,757,000 after acquiring an additional 215,995 shares during the last quarter. Jane Street Group LLC boosted its stake in MiMedx Group by 133.6% in the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock worth $1,806,000 after buying an additional 174,797 shares during the last quarter. Barclays PLC grew its holdings in MiMedx Group by 163.9% in the 3rd quarter. Barclays PLC now owns 262,449 shares of the company's stock valued at $1,550,000 after buying an additional 163,005 shares during the period. LPL Financial LLC increased its stake in shares of MiMedx Group by 213.8% during the 4th quarter. LPL Financial LLC now owns 143,845 shares of the company's stock valued at $1,384,000 after acquiring an additional 98,004 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of MiMedx Group by 6.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company's stock worth $8,483,000 after acquiring an additional 92,726 shares during the period. Hedge funds and other institutional investors own 79.15% of the company's stock.

Remove Ads

MiMedx Group Trading Down 2.6 %

Shares of NASDAQ:MDXG traded down $0.20 during trading on Friday, reaching $7.54. 472,215 shares of the stock were exchanged, compared to its average volume of 704,934. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The firm's 50-day moving average price is $8.27 and its 200 day moving average price is $7.91. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 13.71 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting analysts' consensus estimates of $0.07. The firm had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. On average, sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday, February 27th.

Insider Activity at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO William Frank Iv Hulse sold 54,596 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the sale, the chief accounting officer now owns 440,178 shares in the company, valued at $3,473,004.42. This trade represents a 11.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock valued at $1,130,312 over the last three months. 1.30% of the stock is owned by insiders.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.